$TransMedics(TMDX.US) | Stifel reiterates ๐๐จ๐ฅ๐ on ๐๐ซ๐๐ง๐ฌ๐๐๐๐ข๐๐ฌ, maintains ๐๐ ๐๐ญ $๐๐
Analyst sees near-term caution, flagging that a Q2 revenue beat is less likely due to 'dry-runs' and that 2026/27 EPS estimates may need a reset.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments